Latest from John Theurer Cancer Center

Physicians at the John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics's novel therapy, GDC-0084, for glioblastoma.

Andrew L. Pecora, MD, discusses the use of autologous stem cell transplantation in patients aged ≥75 years and the future of care in multiple myeloma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Hackensack Meridian Health John Theurer Cancer Center at Hackensack University Medical Center will host its tenth annual Celebrating Life and Liberty event at MetLife Stadium September 14. 

Hackensack Meridian Health, New Jersey’s largest and most comprehensive healthcare network, is proud to announce the opening of the Institute for Multiple Myeloma which will support groundbreaking research to enhance treatment of this rare cancer.

Noa Biran, MD, discusses patient-reported outcomes following autologous stem cell transplant in patients with myeloma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).